Evaluation of drugs acting on CB1-A2A receptor oligomers in rat models of Parkinson's disease (Abstract/Poster in atti di convegno)

Type
Label
  • Evaluation of drugs acting on CB1-A2A receptor oligomers in rat models of Parkinson's disease (Abstract/Poster in atti di convegno) (literal)
Anno
  • 2011-01-01T00:00:00+01:00 (literal)
Alternative label
  • N. Simola1, G. Costa1, C.E. Muller2, M.T. Armentero3, R. Franco4, A. Pinna5 (2011)
    Evaluation of drugs acting on CB1-A2A receptor oligomers in rat models of Parkinson's disease
    in XIX World Congress on Parkinson's Disease and Related Disorders, Shangai, Cina, 11-14 dicembre
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • N. Simola1, G. Costa1, C.E. Muller2, M.T. Armentero3, R. Franco4, A. Pinna5 (literal)
Note
  • Poster (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1Department of Toxicology, University of Cagliari, Cagliari, Italy, 2PharmaCenter Bonn, Pharmaceutical Institute, University of Bonn, Bonn, Germany, 3IRCCS National Neurological Institute C. Mondino, Pavia, Italy, 4Department of Biochemistry & Molecular Biology, University of Barcelona, Barcelona, Spain, 5Institute of Neuroscience, CNR-National Research Council, Cagliari, Italy (literal)
Titolo
  • Evaluation of drugs acting on CB1-A2A receptor oligomers in rat models of Parkinson's disease (literal)
Abstract
  • It has recently been demonstrated that adenosine A2A receptors (A2AR) may interact at the striatal level with cannabinoid CB1 receptors (CB1R), leading to the formation of G protein-coupled receptor heteromers; these interactions have been suggested to participate in the antiparkinsonian effects of A2AR antagonists. To clarify this issue, we investigated the effects of a new drug combination interacting with A2AR and CB1R in rat models of Parkinson's disease (PD). The CB1R antagonist rimonabant, and the adenosine A2AR antagonist MSX-3 were administered alone, in combination, or togehter with a sub-threshold dose of L-DOPA in two PD models: 1) contralateral turning behavior in rats bearing a unilateral lesion induced by the dopaminergic neurotoxin 6-hydroxydopamine (6-OHDA); 2) tremulous jaw movements induced in rats by the acethylcholinesterase inhibitor tacrine. In 6-OHDA-lesioned rats, administration of either rimonabant (1 mg/ kg) or MSX-3 (3 mg/ kg i.p.), or of their combination did not stimulate contralateral turning. Moreover, rimonabant (1 mg/kg) did not amplify L-DOPA-induced contralateral turning, whilst MSX-3 (3 mg/kg) significantly potentiated this effect of L-DOPA. However, the combined administration of rimonabant (1 mg/kg) and MSX-3 (3 mg/kg) did not further amplify L-DOPA-induced contralateral turning when compared to the administration of MSX-3 (3 mg/kg) alone. Finally, rimonabant (1 mg/kg) and MSX-3 (3 mg/kg), administered either alone or in combination, did not significantly counteract tremulous jaw movements induced by tacrine. Taken together, these results suggest that the interaction with CB1R might not be a critical mechanism for the mediation of antiparkinsonian effects by A2AR antagonists. (literal)
Prodotto di
Autore CNR

Incoming links:


Autore CNR di
Prodotto
data.CNR.it